wiki pageCreated: 2026-04-02T07:20:06By: crosslink-migrationQuality:
50%✓ SciDEXID: wiki-companies-reprocells-inc
📖 Wiki Page
company914 wordssynced 2026-04-02
Overview
ReproCELL Inc. (リプロセル株式会社) is a Japanese biotechnology company headquartered in Tokyo, specializing in induced pluripotent stem cell (iPSC) technology and regenerative medicine for drug discovery. Founded in 2013 as a spin-off from [Kyoto University's Center for iPS Cell Research and Application (CiRA)](https://www.cira.kyoto-u.ac.jp/), ReproCELL has established itself as a leading provider of iPSC-derived products and services for neurodegenerative disease modeling and drug screening[@reprocell_co].
The company traces its origins to technology developed under Professor Shinya Yamanaka, whose discovery of iPSCs earned him the Nobel Prize in Physiology or Medicine in 2012. This prestigious academic lineage has positioned ReproCELL at the forefront of iPSC-based research tools for pharmaceutical companies worldwide.
ReproCELL's core technology platform centers on three key capabilities:
iPSC Derivation and Banking
The company maintains a library of clinically characterized iPSC lines including[@ipsc_neuro]:
...
Overview
ReproCELL Inc. (リプロセル株式会社) is a Japanese biotechnology company headquartered in Tokyo, specializing in induced pluripotent stem cell (iPSC) technology and regenerative medicine for drug discovery. Founded in 2013 as a spin-off from [Kyoto University's Center for iPS Cell Research and Application (CiRA)](https://www.cira.kyoto-u.ac.jp/), ReproCELL has established itself as a leading provider of iPSC-derived products and services for neurodegenerative disease modeling and drug screening[@reprocell_co].
The company traces its origins to technology developed under Professor Shinya Yamanaka, whose discovery of iPSCs earned him the Nobel Prize in Physiology or Medicine in 2012. This prestigious academic lineage has positioned ReproCELL at the forefront of iPSC-based research tools for pharmaceutical companies worldwide.
ReproCELL's core technology platform centers on three key capabilities:
iPSC Derivation and Banking
The company maintains a library of clinically characterized iPSC lines including[@ipsc_neuro]:
Disease-specific lines: iPSCs derived from patients with Alzheimer's disease, Parkinson's disease, and ALS carrying relevant genetic mutations
Isogenic control lines: Gene-edited lines where disease-causing mutations have been corrected to serve as proper controls
Population diversity: Cell lines representing different genetic backgrounds for compound screening
Neural Differentiation Protocols
ReproCELL has developed robust protocols for generating multiple neural cell types from iPSCs:
Dopaminergic neurons: For [Parkinson's disease](/diseases/parkinsons-disease) models — these neurons are the primary cell type lost in PD
Cortical and hippocampal neurons: For [Alzheimer's disease](/diseases/alzheimers-disease) models — studying memory-relevant brain regions
Motor neurons: For ALS models — studying the cell type most affected in ALS
Astrocytes and microglia: Supporting cell types with important roles in neurodegeneration
Disease Modeling
The company creates disease models by differentiating patient-derived iPSCs and characterizing disease-relevant phenotypes[@reprocell_ipsc]:
Amyloid-beta production: Analysis of amyloid processing in patient-derived neurons
Tau phosphorylation: Study of tau pathology and aggregation in AD models
Alpha-synuclein aggregation: Analysis of [alpha-synuclein](/proteins/alpha-synuclein) behavior in PD models
Mitochondrial dysfunction: Assessment of energy metabolism defects in patient cells
Neurodegeneration Programs
Alzheimer's Disease
ReproCELL has developed iPSC-derived neuronal models from Alzheimer's disease patients that enable pharmaceutical partners to:
Screen compounds for effects on amyloid-beta production and secretion
Study tau phosphorylation and the relationship to amyloid pathology
Evaluate synaptic integrity in patient-derived neurons
Identify disease-modifying mechanisms through omics approaches
The company's iPSC platform has been adopted by major pharmaceutical companies for AD drug discovery programs targeting novel mechanisms beyond amyloid.
Parkinson's Disease
For Parkinson's disease research, ReproCELL provides:
Dopaminergic neuron models: iPSC-derived neurons from PD patients for disease modeling
LRRK2 mutation models: Lines carrying the common G2019S LRRK2 mutation to study PD pathogenesis
SNCA triplication models: Lines with [SNCA](/genes/snca) gene multiplication to model alpha-synuclein aggregation
Mitochondrial assays: Functional characterization of mitochondrial defects in PD patient cells
Amyotrophic Lateral Sclerosis (ALS)
ReproCELL has developed iPSC models for ALS, including:
SOD1 mutation lines: Modeling familial ALS with SOD1 mutations
C9orf72 repeat expansion lines: The most common genetic cause of familial ALS
Co-culture systems: Astrocyte-motor neuron co-cultures to study non-cell-autonomous mechanisms
Strategic Partnerships
ReproCELL has established collaborations with major pharmaceutical companies for iPSC-based drug discovery[@astellas_ipc]:
Astellas Pharma: Long-term collaboration on iPSC-based drug discovery for neurological disorders
Takeda Pharmaceutical: Partnership for inflammatory and neurodegenerative disease research
Government collaborations: AMED-funded programs for regenerative medicine and cell therapy development[@amed_reg]
The company also maintains academic collaborations with Japanese and international universities, providing access to cutting-edge research while contributing to the broader scientific community.
Products and Services
Research Products
ReproCELL offers a comprehensive catalog of iPSC-related products:
iPSC lines: Disease-specific and healthy control iPSC lines
Culture media: Optimized media for iPSC maintenance and neural differentiation
Differentiation kits: Complete kits for generating specific neural cell types
Contract Services
For pharmaceutical companies needing customized capabilities:
Custom iPSC generation: From patient samples with full characterization
Disease model development: Creation of patient-specific models for compound screening
Drug screening campaigns: High-throughput screening using iPSC-derived cells
Toxicity assessment: iPSC-based safety pharmacology and toxicity testing
Role in Japan's iPSC Ecosystem
Japan holds a unique position in global iPSC research, with ReproCELL serving as a critical link between basic research and industrial application. The company's position within this ecosystem draws from:
Yamanaka's legacy: Direct connection to the discovery of iPSCs through CiRA provides credibility and access to the latest technology